Efficacy and Safety of Saccharomyces Boulardii in the Treatment of Small Intestinal Bacterial Overgrowth
Status:
Completed
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
Non-constipated irritable bowel syndrome is a common disorder that may be related to small
intestinal bacterial overgrowth. Saccharomyces boulardii CNCM I-745 is a probiotic yeast that
has proven efficacy for the treatment of acute gastroenteritis and antibiotic-associated
diarrhea. However, its efficacy for the treatment of diarrhea-predominant irritable bowel
syndrome with small intestinal bacterial overgrowth has not been assessed. Hence, an
exploratory randomized, open label trial comparing the efficacy and safety of Saccharomyes
boulardii CNCM I-745 plus diet administration versus diet administration only for 15 days
among adult patients with the aforementioned condition was conducted.
Phase:
Phase 4
Details
Lead Sponsor:
Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno